YIH
SLN

Y-Intercept (HK)’s Silence Therapeutics SLN Stock Holding History

Y-Intercept (HK)’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,217
Closed -$146K – 1572
2024
Q4 		$146K Buy
21,217
+139
+0.7% +$1.79K 0.01% 1079
2024
Q3 		$383K Buy
21,078
+3,923
+23% +$73K 0.02% 908
2024
Q2 		$326K Buy
+17,155
New +$365K 0.02% 1005

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Y-Intercept (HK)'s SLN Position: Q1 2025 in Review

Y-Intercept (HK) sold out of Silence Therapeutics (SLN) in Q1 2025, closing a stake of 21,217 shares — an estimated $146K sold.

Y-Intercept (HK) first reported a position in SLN in Q2 2024 and held it in 3 quarters. The position peaked at $383K in Q3 2024. 59 funds tracked by Wall St. Rank hold SLN as of Q1 2025.

  • Y-Intercept (HK) reported no remaining Silence Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 21,217 Silence Therapeutics shares in Q1 2025, an estimated $146K.
  • Y-Intercept (HK) first reported a position in Silence Therapeutics in Q2 2024 and held it in 3 quarters.
  • Y-Intercept (HK)'s Silence Therapeutics position peaked at $383K in Q3 2024.
  • 59 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2025.

Based on Y-Intercept (HK)'s 13F filing for Q1 2025, filed 6 May 2025.